Timing of Initiating Glycopeptide Therapy for Methicillin‐Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome
Year: 2013
Type: article
Study design: Observational Study
Abstract: When a Staphylococcus-like organism (SLO) is microscopically found in Gram staining of blood culture (BC) specimen, it seems reasonable to administrate a glycopeptide (GP) for empirical therapy. The paper investigates the risk factors for 14-day mortality in patients with methicillin-resistance Staphylococcus aureus bacteremia (MRSAB) and clarifies the impact of the timing for initiating GP therapy. A retrospective study identifies patients with MRSAB (endocarditis was excluded) between 2006 and 2009. Patients were categorized as receiving GP at the interval before a preliminary BC report indicating the growth of SLO and the onward 24 hours or receiving GP 24 h after a preliminary BC report indicating the growth of SLO. Total 339 patients were enrolled. There was no difference on the 14-day overall or infection-related mortality rates at the time to administer GP. Multivariate analysis disclosed pneumonia (OR = 4.47; of 95% CI; of 2.09-9.58; P < 0.01) and high APACHE II score (OR, 2.81, with 95% CI, 1.19-6.65; P = 0.02) were independent risk factors for infection-related mortality. The mortality rate did not decrease following administrating GP immediately after a preliminary BC indicating SLO growth. An additional research for the optimal timing for initiating GP treatment is warranted.
Source: The Scientific World JOURNAL
DOI: 10.1155/2013/457435
Authors: Chen-Hsiang Lee, Chun-Chih Chien, Jien-Wei Liu
Institutions: Chang Gung University, Kaohsiung Chang Gung Memorial Hospital
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $860
OpenAlex ID: W2009269646
